文献速递消化道肿瘤放疗放疗物理与技术

直肠癌新辅助放化疗期间每日T2与弥散加权MRI的MR回归模式探索

Exploring MR regression patterns in rectal cancer during neoadjuvant radiochemotherapy with daily T2- and diffusion-weighted MRI.
PubMed 文献 · Radiat Oncol · 2020-07-11

这项前瞻性探索性研究对局部晚期直肠癌患者在新辅助放化疗期间进行每日MRI扫描,基于T2和DWI序列勾画肿瘤体积并计算每日ADC值,分析MR生物标志物对治疗反应的预测价值。8例患者共171次MRI扫描中,4例达到病理完全缓解(pCR),4例为病理部分缓解(pPR);T2和DWI体积测量在治疗反应方面具有统计学显著性,并定义了第2周和第4周预测pCR的体积阈值,而平均肿瘤ADC值在两组间广泛重叠,不足以预测治疗反应。

要点

  • 每日T2和DWI体积测量可早期预测直肠癌新辅助放化疗后的pCR。
  • 第2周和第4周的体积阈值被定义用于预测pCR。
  • 平均肿瘤ADC值在pCR与pPR组间广泛重叠,预测价值不足。

核心结论

  • MRI可能在新辅助放化疗早期预测直肠癌的病理完全缓解,为MR引导的自适应治疗提供依据。

研究设计与样本

  • 前瞻性探索性研究,纳入局部晚期直肠癌患者,在新辅助放化疗期间进行每日MRI扫描,共分析8例患者的171次MRI扫描。

主要发现

  • 4例患者达到病理完全缓解(pCR),4例为病理部分缓解(pPR)。
  • T2和DWI基于的体积测量在治疗反应方面具有统计学显著性。
  • 第2周和第4周定义了预测pCR的体积阈值。
  • 平均肿瘤ADC值在两组反应间广泛重叠,不足以预测治疗反应。

关键数值与推荐

  • 第2周和第4周的体积阈值被定义用于预测pCR,具体数值原文未报告。
  • 平均肿瘤ADC值在pCR与pPR组间广泛重叠,不适用于预测治疗反应。

临床怎么用

  • 可考虑在新辅助放化疗期间利用每日T2和DWI体积测量早期识别可能达到pCR的患者。
  • 平均ADC值不宜单独作为预测治疗反应的生物标志物。

局限性

  • 探索性研究,样本量仅8例患者,结论需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To date, only limited magnetic resonance imaging (MRI) data are available concerning tumor regression during neoadjuvant radiochemotherapy (RCT) of rectal cancer patients, which is a prerequisite for adaptive radiotherapy (RT) concepts. This exploratory study prospectively evaluated daily fractional MRI during neoadjuvant treatment to analyze the predictive value of MR biomarkers for treatment response. METHODS: Locally advanced rectal cancer patients were examined with daily MRI during neoadjuvant RCT. Contouring of the tumor volume was performed for each MRI scan by using T2- and diffusion-weighted-imaging (DWI)-sequences. The daily apparent-diffusion coefficient (ADC) was calculated. Volumetric and functional tumor changes during RCT were analyzed and correlated with the pathological response after surgical resection. RESULTS: In total, 171 MRI scans of eight patients were analyzed regarding anatomical and functional dynamics during RCT. Pathological complete response (pCR) could be achieved in four patients, and four patients had a pathological partial response (pPR) following neoadjuvant treatment. T2- and DWI-based volumetry proved to be statistically significant in terms of therapeutic response, and volumetric thresholds at week two and week four during RCT were defined for the prediction of pCR. In contrast, the average tumor ADC values widely overlapped between both response groups during RCT and appeared inadequate to predict treatment response in our patient cohort. CONCLUSION: This prospective exploratory study supports the hypothesis that MRI may be able to predict pCR of rectal cancers early during neoadjuvant RCT. Our data therefore provide a useful template to tailor future MR-guided adaptive treatment concepts.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Bostel T, Dreher C, Wollschläger D, et al. Exploring MR regression patterns in rectal cancer during neoadjuvant radiochemotherapy with daily T2- and diffusion-weighted MRI. Radiat Oncol. 2020. PMID: 32653003. doi:10.1186/s13014-020-01613-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。